The dual therapy with SIT and Omalizumab is effective and has a good safety and tolerability. Patients reported a significant subjective improvement of life quality without avoiding their work activity. Drug use resulted to be reduced. Therefore, patients will be adherent even when the treatment must be carried out throughout the entire working life.